DemoPrEP

Status

Ongoing

Phase

Demo Project

Principal Investigator(s)

Beatriz Grinsztejn

Objective

Assess the acceptability, feasibility and safety of daily, oral TDF/FTC as PrEP over 12 months.

Prevention Option(s)

PrEP

Study Design

Uncontrolled

Open label

Arms and Assigned Interventions

Description

Fixed dose combination of emtricitabine (FTC) / tenofovir (TDF) (200/300 mg) once daily orally.

Mode of Delivery

Tablet

Products

TDF/FTC (Truvada)

ARMs

Experimental

Official Code

Trial Sponsors

University of Sao Paulo; Centro de Referência e Treinamento DST AIDS; Oswaldo Cruz Foundation

January 2014

January 2016

Enrollment

400

Years

Population

Women

MSM

Sites

Rio de Janeiro

Brazil

You are here